KRAS and non-small cell lung carcinoma: Targeted inhibition of glutaminase (GLS) has been shown to synergistically enhance the anti-tumor activity of selumetinib in KRAS-mutant non-small cell lung cancer (NSCLC), suggesting that copper metabolism-related pathways could offer novel therapeutic strategies for targeting KRAS in breast cancer [83].